Conditions: Pancreatic Carcinoma Non-resectable Stage IV Pancreatic Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Detailed description:
This study will help determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly, opposed to a weekly, dosing schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Arms:
arm 1: Gemcitabine (1,000 mg/m\^2) administered intravenously on days 1 and 15, every 28 days

nab-Paclitaxel (125 mg/m\^2) administered intravenously on days 1 and 15, every 28 days

Interventions: intervention 1: Gemcitabine intervention 2: nab-Paclitaxel
Intervention descriptions: intervention 1: Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion intervention 2: Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion

Protocol document: